Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure

The legacy context of general health and science information has long provided a foundation for understanding broad medical risks and therapeutic benefits. Within this framework, public health communication traditionally emphasizes disease prevention, treatment efficacy, and safety profiles of widely used medications. Fosamax, a bisphosphonate prescribed for osteoporosis, exemplifies this heritage: its role in bone density management is well-documented, yet emerging concerns about rare adverse effects have shifted focus toward specific patient populations. This transition from general health awareness to occupational exposure begins by recognizing that certain professional environments may involve heightened contact with pharmaceutical compounds or their manufacturing byproducts. Workers in pharmaceutical production, healthcare settings, or waste management could encounter Fosamax or related substances through inhalation, dermal contact, or accidental ingestion. Such exposure scenarios raise questions about cumulative risk, particularly when considering the biological pathways that might link bisphosphonate presence to conditions like osteonecrosis of the jaw. The pivot here is not to assert causation but to acknowledge that occupational contexts introduce variables—such as repeated low-level exposure or lack of medical oversight—that differ from typical patient use. Thus, the legacy of general health information now converges with industrial hygiene principles, prompting a careful examination of how workplace environments might modulate the risk profile of a drug originally designed for therapeutic benefit.

Bridging to Medical Evidence

Building on the occupational context, it is essential to examine the medical evidence that links Fosamax to osteonecrosis of the jaw (ONJ). Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence. However, a serious adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of exposed bone that persist for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is primarily clinical, based on visual examination and patient history, and may be supported by imaging studies to assess the extent of bone involvement. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Animal Studies

The scientific evidence connecting Fosamax to ONJ is supported by multiple lines of investigation. Mechanistic pathways linking bisphosphonates to jaw osteonecrosis involve the drug's potent inhibition of osteoclast activity, which suppresses bone turnover. This suppression can impair the jawbone's ability to remodel and repair microdamage, particularly after dental procedures or local trauma. The jawbone may be uniquely susceptible due to its high rate of remodeling and exposure to oral microbiota. Multiscale characterization of jawbone in animal models treated with bisphosphonates, including alendronate (the active ingredient in Fosamax), has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). These studies examine tissue mineral density distribution, mechanical stability of teeth in the alveolar socket, and nanoindentation properties of the jawbone matrix, revealing alterations that may predispose to ONJ.

Timeline and Risk Factors

The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Additionally, the risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This suggests that both short-term and long-term users can be affected, though longer use appears to elevate risk. Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label notes that in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event that may not have been fully captured in premarketing trials.

Causation Considerations for Affected Patients

For affected patients, causation-related considerations are complex. The presence of known risk factors, such as dental procedures or cancer therapies, can confound the attribution of ONJ solely to Fosamax. Nonetheless, the temporal relationship—symptoms developing after starting the drug, with relief upon discontinuation and recurrence upon rechallenge in a subset of patients—supports a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who develop ONJ while on Fosamax should be evaluated for other risk factors, and the drug should be discontinued if severe symptoms develop. In summary, the scientific evidence establishes a plausible causal connection between Fosamax and osteonecrosis of the jaw, supported by clinical reports, mechanistic studies, and pharmacological data. The risk is modulated by duration of use, dental procedures, and other patient-specific factors. While warnings exist in the prescribing information, the rarity of the event and the presence of confounding factors require careful clinical assessment for each affected patient.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis. It works by inhibiting bone resorption, which increases bone mass and reduces fracture incidence. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, persisting for more than eight weeks, often with pain, swelling, infection, or drainage. Diagnosis is primarily clinical, based on visual examination and patient history, and may be supported by imaging. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What is the scientific evidence linking Fosamax to ONJ?

Evidence includes clinical reports, mechanistic studies showing bisphosphonate inhibition of osteoclast activity leading to suppressed bone turnover, and animal model studies revealing jawbone-specific alterations. The temporal relationship and recurrence upon rechallenge support a causal link. (https://pubmed.ncbi.nlm.nih.gov/40345077/)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.